FORUS Therapeutics is thrilled to announce Weihao Tang as Senior Product Manager. Weihao brings more than 10 years of experience across the pharmaceutical and clinical diagnostics industries, combining a strong scientific foundation with broad commercial expertise....
FORUS Therapeutics is thrilled to announce Marie-Eve Caron as Associate Director, Sales. Marie-Eve brings more than 20 years of pharmaceutical experience, including over 13 years in specialty care across immunology and hematology/oncology. Throughout her career, she...
(OAKVILLE, Ontario) 6 juillet 2026 – FORUS Therapeutics Inc (« FORUS »), une filiale en propriété exclusive de PharmaEssentia Corp, a le plaisir d’annoncer qu’elle a reçu un avis de conformité (AC) autorisant BESREMIMD (ropeginterféron alfa-2b) pour le traitement des...
(OAKVILLE, Ontario) June 11, 2026 – FORUS Therapeutics Inc (“FORUS”) is pleased to announce that it has been acquired by PharmaEssentia Corporation, a global biopharmaceutical company focused on developing innovative therapies for hematology, oncology, and...
We are pleased to announce that Marie-Josèphe Champagne has returned to FORUS as Senior Medical Science Liaison (MSL) for Quebec and Atlantic. Marie-Josèphe brings extensive experience from her recent role as National MSL Manager for Hematology, along with more than a...
FORUS Therapeutics Inc. a le plaisir d’annoncer que XPOVIO® (sélinexor) bénéficie désormais d’un financement public au Québec depuis le 6 novembre. Pour plus de détails sur les critères, consultez les liens ci-dessous : Liste des médicaments – Établissement...
Recent Comments